Abstract
The Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA) regulates gene therapies, among other products. The approval of four gene therapy products since 2017 represents a significant milestone for a new class of treatments with the potential to treat or cure diseases, particularly rare diseases, that were previously considered incurable. Several factors have contributed to the recent rapid development of gene therapies including advances in genetics to facilitate target-detection, advances in vectors, and regulatory incentives such as breakthrough therapy designation, priority review and market exclusivity. The patient population affected by a rare disease is typically small, heterogeneous and geographically dispersed. As a result, clinical trials on a rare disease have unique features in terms of study design, subject enrollment, data analyses and interpretation of study results. Given that the patient population affected is small for rare diseases, providing substantial evidence of effectiveness and evidence of safety in trials for rare disease presents challenges. In this paper, we share our experiences in the statistical review of three gene therapy products that have been approved by FDA CBER. Our motivation in writing this paper is to encourage the use of appropriate analysis strategies for other similar small trials, with a focus on data visualization strategies.
This is a preview of subscription content, log in via an institution to check access.
Source: Gene Therapy, Somatic Cell Therapy, and Xenotransplantation IND/IDE Statistical Report, CBER, FDA
Similar content being viewed by others
References
US Food and Drug Administration: FDA Draft Guidance for Industry. Rare Diseases: Common Issues in Drug Development, January 2019.
US Food and Drug Administration: Guidance for Industry – Human Gene Therapy for Rare Diseases, January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases.
US Food and Drug Administration: Guidance for Industry. Chemistry, Manufacturing, and Controls (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug.
US Food and Drug Administration: Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), April 2008.
US Food and Drug Administration: Guidance for Industry – Human Gene Therapy for Hemophilia, January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-hemophilia.
US Food and Drug Administration: Guidance for Industry – Human Gene Therapy for Retinal Disorders, January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-retinal-disorders.
US Food and Drug Administration: Guidance for Industry – Long Term Follow-up After Administration of Human Gene Therapy Products, January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products.
US Food and Drug Administration: Guidance for Industry – Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up, January 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during.
US Food and Drug Administration: Guidance for Industry: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, February 2019. https://www.fda.gov/media/120267/download.
US Food and Drug Administration: Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics, May 2014. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
Guidance for Industry: ICH E10 Choice of Control Group and Related Issues in Clinical Trials, March 2001. https://database.ich.org/sites/default/files/E10_Guideline.pdf.
Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34.
KYMRIAH FDA approval supporting documents clinical review memo https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel.
USPI for BLINCYTO®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf.
USPI for CLOLAR®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021673s010lbledt.pdf.
Maude SL, Laetsch TW, Cuechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.
Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T. Current and evolving methods to visualize biological data in cancer research. J Natl Cancer Inst. 2016;108(8):031.
ZOLGENSMA FDA. Summary Basis of Regulatory Action. https://www.fda.gov/media/127961/download.
Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant TEST of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155–61.
De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26(11):754–9.
Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–7.
Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinalmuscular atrophy. Ann Neurol. 2017;82(6):883–91.
FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss FDA News Release, December 18, 2017. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss.
Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018;46(3):247–59. https://doi.org/10.1111/ceo.13022.
U.S. Food and Drug Administration. Rare Diseases: Natural History Studies for Drug Development – Draft Guidance. March 2019. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM634062.pdf.
U.S. Food and Drug Administration: FDA Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, 2018.
Duke SP, Bancken F, Crowe B, Soukup M, Botsis T, Forshee R. Seeing is Believing: good graphic design principles for medical research. Special Issue: Papers from the Seventh International French Society of Statistics Meeting on Statistical Methods in Biopharmacy: Emerging Topics for Statistical Methodology in Clinical Drug Development. Stat Med. 2015;34(22):3040–59. https://doi.org/10.1002/sim.6549.
Funding
No funding resources.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
No conflict of interest.
Additional information
Disclaimer This article reflects views of the authors and should not be construed to represent the views or policies of US FDA.
Rights and permissions
About this article
Cite this article
Lin, X., Lee, S., Scott, J. et al. Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications. Ther Innov Regul Sci 55, 346–359 (2021). https://doi.org/10.1007/s43441-020-00219-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-020-00219-y